1834610-13-7

1834610-13-7 structure

Name: Lumasiran
Chemical Name: Lumasiran
CAS Number: 1834610-13-7
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Metabolic Disease
Create Date: 2022-02-03 00:13:53
Modify Date: 2024-01-03 13:23:18
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1)[1][2].

Name	Lumasiran

Description	Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1)[1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
In Vitro	Lumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1[1].
In Vivo	Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent[2].
References	[1]. Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81(2):277-282. [2]. Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021;384(13):1216-1226.

No Any Chemical & Physical Properties